Cardiovascular Evidence for Incretin Analogues: A 2026 Review
The past decade has seen a remarkable shift in how we view incretin-based therapies. What started as glucose-lowering antidiabetic agents has become a cardiovascular drug class with proven outcome benefit across multiple clinical scenarios.
The State of the Evidence
A 2026 state-of-the-art review in Frontiers in Endocrinology synthesizes the cardiovascular evidence base for incretin analogues across five clinical scenarios:
- Type 2 diabetes with established atherosclerotic cardiovascular disease or high cardiovascular risk
- Overweight or obesity with established cardiovascular disease but without diabetes
- Obesity-related heart failure with preserved ejection fraction
- Chronic kidney disease
- Symptomatic peripheral artery disease
The review examines pharmacology and proposed cardiovascular mechanisms, including direct effects on the vascular endothelium, macrophage inflammation, and epicardial adipose tissue, alongside indirect benefits mediated by weight loss, glycemic control, and blood pressure reduction.
Pipeline Agents: Retatrutide and Beyond
The review identifies several pipeline agents under investigation for their cardiovascular effects:
- Retatrutide — triple-agonist (GIP/GLP-1/Glucagon)
- CagriSema — amylin + GLP-1 combination
- Survodutide — GLP-1/glucagon dual agonist
- Orforglipron — oral non-peptide GLP-1 agonist
- Zenagamtide — long-acting GLP-1
- MariTide — amylin/GIP dual agonist
Each is being evaluated in ongoing cardiovascular outcome trials.
The Global Access Perspective
A dedicated section of the review examines the global access perspective, including the disproportionately high burden of cardiometabolic disease in low- and middle-income countries, the limited representation of regional populations in pivotal trials, and the structural barriers of cost and reimbursement that constrain access.
Implications for Research-Grade Manufacturing
For peptide manufacturers, this evolution means demand for incretin-class peptides is likely to grow substantially. Manufacturers must keep pace with:
- Purity standards — research and clinical use require ≥98% HPLC, often ≥99%
- Scale — pipeline trials may require kilogram-scale lots
- Reproducibility — academic and industrial users need consistent batch-to-batch quality
- Documentation — CoA, mass spec, and stability data are now baseline expectations
References
- Araiza-Garaygordobil D, et al. Incretin analogues as cardiovascular agents: a state-of-the-art review. Front Endocrinol (Lausanne). 2026;17:1898812. PMID: 42568490. DOI: 10.3389/fendo.2026.1898812